**The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk**

Göran Walldius

94 Lipoproteins – Role in Health and Diseases

2008; 5: 319-335

69-75

276: 875-881

5: 395-403

Lett 2011d; 32:317-321

Thromb Vasc Biol. 2005; 25: 553-559

men. Atherosclerosis 1996; 125: 231-42

subjects. Neureoendocrinol Lett 2011b; 32: 322-327

Patients with Stroke. Cerebrovasc Dis 2009; 27: 99-104

cardiovascular disease. Am J Cardiol 2006; 97: 3A-11A

men : 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler

[44] Fruchart JC, Sacks FM, Hermans MP et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes Vasc Res

[45] Chun Xia Zhao, Ying Hua Cui, Qiao Fan, Pei Hua Wang, Ruitai Hui, Cianflone K, Dao Wen Wang. Small Dense Low-Density Lipoproteins and Associated Risk Factors in

[46] Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus and

[47] Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Small dense LDL lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95:

[48] Gardner CD, Fortman SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;

[49] Rajman I, Kendall MJ, Cramb R, Holder RL, Salih M, Gammage MD. Investigation of low density lipoprotein subfractions as a coronary risk factor in normotriglyceridaemic

[50] Halle M, Berg A, Baumstark MW, Keul L. LDL-Subfraktionen und koronare

[51] Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr.Opinion Lipidol 1994;

[52] Oravec S, Gruber K, Dostal E, Mikl J. Hyper-betalipoproteinenmia LDL1,2: a newly identified non-atherogenic hypercholesterolemia in a group of hypercholesterolemic

[53] Oravec S, Dostal E, Dukat A, Gavorník P, Kucera M, Gruber K. HDL subfractions analysis: A new laboratory diagnostic assay for patients with cardiovascular diseases

[54] Oravec S, Dukat A, Gavorník P, Lovásová Z, Gruber K. Atherogenic normolipidemia – a new phenomenon in the lipoprotein of clinically healthy subjects. Neuroendocrinol

Herzerkrankung – Eine Übersicht. Zeitschrift Kardiol 1998; 87: 317-30

and dyslipoproteinemia. Neuroendocrinol Lett 2011c; 32: 502-509

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/47869
